Subscribe To
PRTA / Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future
Content Topics
Prothena
Biosciences
Unique
Approach
Protein
Misfolding
Biosciences
Future
Stock
PRTA
PRTA News
By Zacks Investment Research
November 3, 2023
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY. more_horizontal
By Zacks Investment Research
November 2, 2023
Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates
Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares more_horizontal
By Zacks Investment Research
October 17, 2023
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the more_horizontal
By Proactive Investors
October 16, 2023
Prothena shares buoyed by sale rumors
Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data f more_horizontal
By Reuters
October 16, 2023
Prothena prepares for potential sale - Bloomberg News
Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter. more_horizontal
By Seeking Alpha
September 21, 2023
Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX more_horizontal
By Zacks Investment Research
September 7, 2023
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates. more_horizontal
By Zacks Investment Research
August 4, 2023
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-lin more_horizontal